MLYS
$25.02
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone ...
Recent News
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 11 Best Day Trading Stocks to Buy Now. Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for its lorundrostat drug to treat hypertension when combined with […]
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Mineralys Therapeutics, Inc.'s Q4 2025 earnings call
Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Mineralys Therapeutics Inc (MLYS) reports strong financials and FDA progress for Laundrostat, while navigating competitive pressures and strategic planning for market entry.